Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer

Abstract

Cell cycle regulators cyclin D1 and cyclin E2 function in G1/S transition by activating downstream cyclin-dependent kinases. Deregulated expression of these cyclins has been reported in various cancers. However, little is known about their clinical significance in gastric carcinoma. We aimed to explore that whether there is differential expression of these cyclins in clinically distinct gastric cancer patients. In this study we recruited a total of 92 subjects including 20 controls and 72 cases of histopathologically proven gastric carcinoma. Expression profiling at transcript level was done by semiquantitative RT-PCR and of protein by immunohistochemistry. Receiver operator characteristics analysis was done for determining diagnostic utility of cyclin D1 and cyclin E2. We demonstrate that cyclins D1 and E2 are frequently overexpressed in early stages of gastric carcinoma. Interestingly, expression of cyclins D1 and E2 significantly correlates with different clinical parameters such as gender, histological type (intestinal and diffuse), tumor location (proximal, middle, and distal), tumor differentiation (differentiated and undifferentiated), tumor invasion (serosal, lymphatic, and venous) and tumor metastasis (lymph node, peritoneal, ascites, and liver). Cyclin D1 has significantly higher sensitivity and specificity as diagnostic biomarker than cyclin E2. Our results suggest that overexpression of cyclin D1 and cyclin E2 is an early event in gastric carcinogenesis. The differential expression of these cyclins may be useful as diagnostic biomarkers for early detection of gastric carcinoma.

UBE2T knockdown inhibits gastric cancer progression

“…CCND1, which is required for progression through the G1 phase of the cell cycle, is rapidly synthesized during that phase and then degraded during S phase. CCND1 also dimerizes with cyclin-dependent kinases (CDK) 4/6 to regulate the G1-S phase transition and inhibits retinoblastoma protein (pRb) activity, and overexpression of CCND1 is associated with tumor progression in gastric and other cancers [31, 32]. Surprisingly, we found that UBE2T knockdown resulted in cell cycle arrest at the G2/M phase rather than the G1/S phase.…”

Apolipoprotein C1 stimulates the malignant process of renal cell carcinoma via the Wnt3a signaling

“…A growing number of studies have detected the abnormally activated Wnt signaling during tumor process [30,31]. The protein encoded by CCND1 belongs to the highly conserved cyclin family, and its members have a signi cant periodicity of protein abundance throughout the cell cycle progression [32]. CCND1 variation is frequently observed during tumor process [33].…”

MicroRNA-720 inhibits pancreatic cancer cell proliferation and invasion by directly targeting cyclin D1

“…The CCND1 gene, located on chromosome 11q13, is a well-known oncogene that is frequently overexpressed in various kinds of human cancers, such as breast cancer (34), lung cancer (35), gastric cancer (36) and bladder cancer (37). In pancreatic cancer, CCND1 was overexpressed in tumour tissues; the expression of this gene is significantly correlated with extent of differentiation and poor prognosis (38,39).…”